Cargando…
Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that express neuropeptides as synaptophysin, chromogranin A (CgA), and specific neuronal enolase (NSE), among others. Vasopressin (AVP) is a neuropeptide with an endocrine, paracrine, and autocrine effect in normal and patho...
Autores principales: | Pifano, Marina, Garona, Juan, Capobianco, Carla S., Gonzalez, Nazareno, Alonso, Daniel F., Ripoll, Giselle V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276816/ https://www.ncbi.nlm.nih.gov/pubmed/28194370 http://dx.doi.org/10.3389/fonc.2017.00011 |
Ejemplares similares
-
Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
por: Ripoll, Giselle V., et al.
Publicado: (2020) -
Preclinical Efficacy of [V(4)Q(5)]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
por: Garona, Juan, et al.
Publicado: (2019) -
Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model
por: Ripoll, Giselle V., et al.
Publicado: (2013) -
The novel desmopressin analogue [V(4)Q(5)]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
por: GARONA, JUAN, et al.
Publicado: (2015) -
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial
por: Iseas, Soledad, et al.
Publicado: (2020)